GLP-1 Drugs Explained: Clinical Evidence and Options
GLP-1 drugs clinical evidence supports their use in managing type 2 diabetes and weight loss. These medications improve glycemic control and reduce cardiovascular risk. Understanding their clinical benefits and side effects is essential for effective…
GLP-1 Receptor Agonists: Clinical Evidence & Results
GLP-1 receptor agonist clinical evidence weight management highlights the efficacy of these medications in reducing body weight and improving metabolic health. This evidence supports their use in patients with obesity and type 2 diabetes. Clinicians…
Clinical Evidence for GLP-1 Receptor Agonists in Metabolic Health
GLP-1 receptor agonist clinical evidence metabolic health highlights their role in weight management and cardiovascular benefits. Understanding patient selection and safety monitoring is essential. These agents support comprehensive metabolic care beyond…
Policy Watch: 20 Regulatory Updates — June 21, 2026
This Policy Watch covers schedules of controlled substances placement June 2026 updates with 20 key regulatory items. The DEA's recent actions focus on synthetic cannabinoids and other substances. These changes affect clinical relevance and regulatory…
Schedules of Controlled Substances: Rescheduling FDA-Approved Cannabis Products
The FDA approved cannabis products rescheduling from Schedule I to Schedule III marks a significant regulatory shift. This change facilitates improved medical access and reduces administrative burdens for clinicians. It specifically applies to…
Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
The DEA scheduling synthetic cannabinoids 2026 update places 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA into Schedule I. These substances have high abuse potential and no accepted medical use. Clinicians should be aware of the risks…
DEA Places Synthetic Cannabinoid CUMYL-PEGACLONE in Schedule I
The DEA synthetic cannabinoids schedule I placement 2026 update officially classifies CUMYL-PEGACLONE as a Schedule I substance. This reflects the ongoing challenge of regulating synthetic cannabinoids with high abuse potential. Clinicians should be…
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The DEA has temporarily placed 2-fluorodeschloroketamine into Schedule I due to its abuse potential and lack of accepted medical use. This scheduling highlights regulatory challenges with novel psychoactive substances. Clinicians should be aware of…
Diphenidine Placement in Schedule I Controlled Substances
The DEA has designated diphenidine as a diphenidine schedule i controlled substance due to its high abuse potential and lack of accepted medical use. This synthetic dissociative drug is structurally related to other regulated substances and has emerged…
Cannabis branding may appeal to youth despite regulations, study finds
✦ New CED Clinical Relevance #37 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyResearchSafetyIndustryPediatricsAnxietyMental Health Why This Matters Clinicians need to understand that current…